Phio Pharmaceuticals Corp Stock Fundamentals
| PHIO Stock | USD 2.53 0.15 6.30% |
Phio Pharmaceuticals Corp fundamentals help investors to digest information that contributes to Phio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Phio Stock. The fundamental analysis module provides a way to measure Phio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phio Pharmaceuticals stock.
At this time, Phio Pharmaceuticals' Interest Expense is very stable compared to the past year. As of the 22nd of November 2024, Total Operating Expenses is likely to grow to about 8.6 M, while Depreciation And Amortization is likely to drop about 125.1 K. Phio | Select Account or Indicator |
Phio Pharmaceuticals Corp Company Return On Equity Analysis
Phio Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Phio Pharmaceuticals Return On Equity | -1.27 |
Most of Phio Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phio Pharmaceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Phio Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Phio Pharmaceuticals Corp has a Return On Equity of -1.2686. This is 94.71% lower than that of the Biotechnology sector and 96.52% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Phio Pharmaceuticals Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Phio Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Phio Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Phio Pharmaceuticals competition to find correlations between indicators driving Phio Pharmaceuticals's intrinsic value. More Info.Phio Pharmaceuticals Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Phio Pharmaceuticals' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Phio Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Phio Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phio Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phio Pharmaceuticals by comparing valuation metrics of similar companies.Phio Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Phio Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Phio Pharmaceuticals from analyzing Phio Pharmaceuticals' financial statements. These drivers represent accounts that assess Phio Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Phio Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.3M | 4.3M | 12.3M | 5.1M | 5.8M | 5.5M | |
| Enterprise Value | (12.6M) | (2.1M) | (1.3M) | (6.4M) | (7.4M) | (7.0M) |
Phio Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Phio Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Phio Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Phio Fundamentals
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | (5.94 M) | ||||
| Shares Outstanding | 860.72 K | ||||
| Shares Owned By Insiders | 5.89 % | ||||
| Shares Owned By Institutions | 2.07 % | ||||
| Number Of Shares Shorted | 51.49 K | ||||
| Price To Earning | (0.80) X | ||||
| Price To Book | 0.51 X | ||||
| Price To Sales | 48.01 X | ||||
| Gross Profit | (7.01 M) | ||||
| EBITDA | (10.64 M) | ||||
| Net Income | (10.83 M) | ||||
| Cash And Equivalents | 18.02 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 35 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 7.39 X | ||||
| Cash Flow From Operations | (10.75 M) | ||||
| Short Ratio | 0.50 X | ||||
| Earnings Per Share | (14.81) X | ||||
| Target Price | 36.0 | ||||
| Beta | 1.47 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 9.36 M | ||||
| Retained Earnings | (139.21 M) | ||||
| Working Capital | 7.69 M | ||||
| Current Asset | 9.23 M | ||||
| Current Liabilities | 2.17 M | ||||
| Net Asset | 9.36 M |
About Phio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phio Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phio Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.4 M | 1.5 M | |
| Cost Of Revenue | 6.3 M | 4.3 M | |
| Stock Based Compensation To Revenue | 16.43 | 21.55 | |
| Sales General And Administrative To Revenue | 201.77 | 211.86 | |
| Research And Ddevelopement To Revenue | 184.29 | 94.68 | |
| Capex To Revenue | 3.09 | 2.06 | |
| Revenue Per Share | 5.67 | 5.38 | |
| Ebit Per Revenue | (492.15) | (516.75) |
Pair Trading with Phio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Phio Stock
The ability to find closely correlated positions to Phio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phio Pharmaceuticals Corp to buy it.
The correlation of Phio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Phio Pharmaceuticals Piotroski F Score and Phio Pharmaceuticals Altman Z Score analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.81) | Return On Assets (0.61) | Return On Equity (1.27) |
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.